A Year Of Paxlovid - Where Is The Licensed Generic?

Hetero Gets First WHO PQ; Chinese, Korean Companies In The Wings

 
• By Vibha Ravi

A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.

Paxlovid Pill
What Lies Ahead For Authorized Generics of Paxlovid? • Source: Shutterstock

The Medicines Patent Pool was on to a good thing when it signed a licensing agreement with Pfizer for nirmatrelvir while it was still an investigational COVID-19 antiviral treatment candidate PF-07321332. (Also see "Pfizer And MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid" - Generics Bulletin, 17 November, 2021.)

The company went on to package the drug with ritonavir to make Paxlovid, for which it gained an emergency use...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

ViiV Extends Voluntary License For Long-Acting Cabotegravir As HIV Treatment

 
• By Urtė Fultinavičiūtė

The Medicines Patent Pool’s extended voluntary license to produce long-acting cabotegravir to treat HIV is a win for patients living in LMICs, as the WHO updated its guidance to recommend it as an alternative treatment option.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By Sue Sutter

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By Dave Wallace

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.